Department of General Surgery, First Affiliated Hospital, Nanjing Medical University,Nanjing, People's Republic of China.
World J Surg Oncol. 2012 Aug 16;10:163. doi: 10.1186/1477-7819-10-163.
There is no definite agreement on the better therapy (radiofrequency ablation (RFA) versus surgical resection (SR)) for early hepatocellular carcinoma (HCC) eligible for surgical treatments. The purpose of this study is to evaluate the evidence using meta-analytical techniques.
A literature search was undertaken until December 2011 to identify comparative studies evaluating survival rates, recurrence rates, and complications. Pooled odds ratios (OR) and 95% confidence intervals (95% CI) were calculated with either the fixed or random effect model.
Thirteen articles, comprising two randomized controlled trials(RCTs), were included in the review, with a total of 2,535 patients (1,233 treated with SR and 1,302 with RFA). The overall survival rates were significantly higher in patients treated with SR than RFA after1, 3, and 5 years (respectively: OR, 0.60 (95% CI, 0.42 to 0.86); OR, 0.49 (95% CI, 0.36 to 0.65); OR, 0.60 (95% CI, 0.43 to 0.84)). In the SR group, the 1, 3, and 5 years recurrence rates were significantly lower than the RFA group (respectively: OR, 1.48 (95% CI, 1.05 to 2.08); OR, 1.76 (95% CI, 1.49 to 2.08); OR, 1.68 (95% CI, 1.21 to 2.34)). However, local recurrence between two groups did not exhibit significant difference. For HCC ≤ 3 cm in diameter, SR was better than RFA at the 1, 3, and 5 years overall survival rates (respectively: OR, 0.34 (95% CI, 0.13 to 0.89); OR, 0.56 (95% CI, 0.37 to 0.84); OR, 0.44 (95% CI, 0.31 to 0.62)). This meta-analysis indicated that the complication of SR was higher than RFA (OR, 6.25 (95%CI, 3.12 to 12.52); P = 0.000).
Although local recurrence between two groups did not exhibit significant difference, SR demonstrated significantly improved survival benefits and lower complications for patients with early HCC, especially for HCC ≤ 3 cm in diameter. These findings should be interpreted carefully, owing to the lower level of evidence.
对于适合手术治疗的早期肝细胞癌(HCC),射频消融(RFA)与手术切除(SR)哪种疗法更好,目前尚无定论。本研究旨在运用荟萃分析技术评估相关证据。
检索截至 2011 年 12 月的相关文献,以评估比较两种疗法的生存率、复发率和并发症的研究。采用固定或随机效应模型计算汇总优势比(OR)和 95%置信区间(95%CI)。
共纳入 13 项研究(包括 2 项随机对照试验),共计 2535 例患者(SR 治疗组 1233 例,RFA 治疗组 1302 例)。SR 组患者的 1、3、5 年总生存率显著高于 RFA 组(分别为:OR,0.60(95%CI,0.42 至 0.86);OR,0.49(95%CI,0.36 至 0.65);OR,0.60(95%CI,0.43 至 0.84))。SR 组患者的 1、3、5 年复发率显著低于 RFA 组(分别为:OR,1.48(95%CI,1.05 至 2.08);OR,1.76(95%CI,1.49 至 2.08);OR,1.68(95%CI,1.21 至 2.34))。然而,两组患者的局部复发率无显著差异。对于直径≤3cm 的 HCC,SR 组患者的 1、3、5 年总生存率显著高于 RFA 组(分别为:OR,0.34(95%CI,0.13 至 0.89);OR,0.56(95%CI,0.37 至 0.84);OR,0.44(95%CI,0.31 至 0.62))。本荟萃分析表明,SR 组的并发症发生率高于 RFA 组(OR,6.25(95%CI,3.12 至 12.52);P=0.000)。
虽然两组患者的局部复发率无显著差异,但 SR 可显著提高早期 HCC 患者的生存率,降低并发症发生率,尤其是对直径≤3cm 的 HCC。由于证据水平较低,这些发现应谨慎解读。